Related Experiment Video
Updated: Apr 23, 2026
13:04
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
23.7K
A near-full length genotypic assay for HCV1b
Lize Cuypers1, Joke Snoeck1, Bram Vrancken1
1Clinical and Epidemiological Virology, Rega Institute for Medical Research, Department of Microbiology and Immunology, KU Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium.
Journal of Virological Methods
|September 24, 2014
Summary
A new assay can genotype Hepatitis C Virus 1b (HCV1b) near-full genome, aiding antiviral drug resistance studies. Despite challenges with viral variability, it shows promise for resistance mutation detection and epidemiology.
Area of Science:
- Virology
- Genetics
- Molecular Biology
Background:
- Hepatitis C Virus 1b (HCV1b) infection requires effective antiviral therapies.
- Investigating antiviral drug resistance is crucial for managing HCV1b.
- New combination therapies necessitate reliable genotyping methods.
Purpose of the Study:
- To develop a near-full genome genotypic assay for HCV1b.
- To assess the assay's utility in detecting antiviral drug resistance mutations.
- To evaluate the assay's potential for epidemiological research.
Main Methods:
- Development of a near-full genome genotypic assay using three overlapping PCRs.
- Sequencing performed using Sanger population and Illumina next-generation sequencing.
- Assay optimization and validation using 77 therapy-naïve HCV1b samples.
Main Results:
- Median detection limits varied across regions (570 to 56,670 IU/ml).
- Illumina sequencing with Segminator II software showed optimal read mapping (81%).
- High concordance between Illumina and Sanger sequencing, with minor discordances attributed to minority variants.
Conclusions:
- The developed assay is suitable for detecting HCV1b drug resistance mutations.
- The assay can be applied to epidemiological research.
- Challenges in sensitivity and reproducibility were noted due to high viral genetic variability.
